SE7512740L - Sett att framstella en overdragen brusande l-dopaberedning som frigores i tarmen - Google Patents

Sett att framstella en overdragen brusande l-dopaberedning som frigores i tarmen

Info

Publication number
SE7512740L
SE7512740L SE7512740A SE7512740A SE7512740L SE 7512740 L SE7512740 L SE 7512740L SE 7512740 A SE7512740 A SE 7512740A SE 7512740 A SE7512740 A SE 7512740A SE 7512740 L SE7512740 L SE 7512740L
Authority
SE
Sweden
Prior art keywords
intestine
losing
released
preparing
covered
Prior art date
Application number
SE7512740A
Other languages
Unknown language ( )
English (en)
Swedish (sv)
Inventor
K Nishimura
M Arai
K Sasahara
T Nitanai
Original Assignee
Interx Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interx Research Corp filed Critical Interx Research Corp
Publication of SE7512740L publication Critical patent/SE7512740L/

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE7512740A 1974-11-14 1975-11-13 Sett att framstella en overdragen brusande l-dopaberedning som frigores i tarmen SE7512740L (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP49131304A JPS5157813A (en) 1974-11-14 1974-11-14 Ll dooba mataha sonojudotaiseizaino seiho

Publications (1)

Publication Number Publication Date
SE7512740L true SE7512740L (sv) 1976-05-17

Family

ID=15054818

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7512740A SE7512740L (sv) 1974-11-14 1975-11-13 Sett att framstella en overdragen brusande l-dopaberedning som frigores i tarmen

Country Status (10)

Country Link
US (1) US3961041A (enExample)
JP (1) JPS5157813A (enExample)
CA (1) CA1047928A (enExample)
DE (1) DE2551280A1 (enExample)
ES (1) ES442579A1 (enExample)
FR (1) FR2290912A1 (enExample)
GB (1) GB1485676A (enExample)
IT (1) IT1069069B (enExample)
NL (1) NL7513370A (enExample)
SE (1) SE7512740L (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147768A (en) * 1976-09-13 1979-04-03 Interx Research Corporation Enteric coated digoxin and therapeutic use thereof
JPS54138128A (en) * 1978-04-19 1979-10-26 Akiyama Jiyouzai Kk Double contrast medium for intestine
US4289751A (en) * 1979-06-29 1981-09-15 Merck & Co., Inc. Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
GB2130087A (en) * 1982-09-22 1984-05-31 Dr Joachime Helbig Pharmaceutical oral dosage forms of an active agent capable of forming or releasing bicarbonate ions
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
EP0252290B1 (en) * 1986-06-10 1992-06-03 CHIESI FARMACEUTICI S.p.A. Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US4942039A (en) * 1989-05-09 1990-07-17 Miles Inc. Effervescent analgesic antacid composition having reduced sodium content
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US20040151768A1 (en) * 1997-07-23 2004-08-05 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
US7060734B1 (en) 1997-09-09 2006-06-13 Alza Corporation Pharmaceutical coating composition and method of use
JP2001515855A (ja) * 1997-09-09 2001-09-25 アルザ・コーポレーション 薬剤コーティング組成物と使用方法
DE69910183T2 (de) * 1998-03-11 2004-06-03 Grelan Pharmaceutical Co., Ltd., Hamura Darmlösliche sprudelnde zusammensetzungen
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6576250B1 (en) 1998-03-27 2003-06-10 Cima Labs Inc. Pharmaceutical compositions for rectal and vaginal administration
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
DE69942205D1 (de) * 1998-08-13 2010-05-12 Cima Labs Inc Microemulsionen als feste dosisformen zur oralen verabreichung
NZ512030A (en) 1998-11-10 2003-10-31 Teva Pharma Process for manufacture of L-dopa ethyl ester
CA2350304A1 (en) 1998-11-10 2000-05-18 Teva Pharmaceutical Industries, Ltd. Dispersible compositions containing l-dopa ethyl ester
KR100299562B1 (ko) 1998-12-29 2001-11-22 우재영 안정성을극대화시킨5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸유도체함유미세과립
AU2005202472B2 (en) * 1999-04-29 2008-12-18 Cima Labs Inc. Effervescent drug delivery system for oral administration
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
CA2548915C (en) * 2003-12-31 2012-10-16 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
MXPA06007453A (es) * 2003-12-31 2007-01-31 Cima Labs Inc Forma de dosificacion de opiaceo oral efervescente.
US7858121B2 (en) 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
JP2016029034A (ja) * 2014-07-18 2016-03-03 ナノメガ メディカル コーポレイションＮａｎｏｍｅｇａ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 医薬組成物
JP2017203031A (ja) * 2017-07-12 2017-11-16 スティッチング グロニンゲン セントル フォー ドラッグ リサーチ ｐＨ制御パルス送達システム、その調製法及び使用法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3131123A (en) * 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
FR2116256A1 (en) 1970-12-02 1972-07-13 Sobio Lab Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
US3891696A (en) * 1973-11-02 1975-06-24 Interx Research Corp Novel, transient pro-drug forms of l-dopa

Also Published As

Publication number Publication date
IT1069069B (it) 1985-03-25
FR2290912B1 (enExample) 1978-07-28
JPS5436645B2 (enExample) 1979-11-10
JPS5157813A (en) 1976-05-20
CA1047928A (en) 1979-02-06
DE2551280A1 (de) 1976-05-20
GB1485676A (en) 1977-09-14
US3961041A (en) 1976-06-01
FR2290912A1 (fr) 1976-06-11
NL7513370A (nl) 1976-05-18
ES442579A1 (es) 1978-01-16

Similar Documents

Publication Publication Date Title
SE7512740L (sv) Sett att framstella en overdragen brusande l-dopaberedning som frigores i tarmen
NO140300C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive (omega-1)-oksodialkylxantiner
DK143221C (da) Fremgangsmaade til fremstilling af et laegemiddel i folieform til oral eller topisk anvendelse
IT7849462A0 (it) Corpo di capsula in particolare per una capsula per la somministrazione di sostanze medicamentose come pure procedimento e dispositivo per lasua produzione
PH12959A (en) Preparation of pharmaceutical unit dosage form
SE425715B (sv) Forfarande for framstellning av ett aminosyrapreparat, avsett for administration till humanpatienter med leversjukdom
BR7308097D0 (pt) Capsula dental misturadora
SE409286B (sv) Sett att framstella en fast, terapeutisk beredning for oralt bruk
NO145382C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-amino-indazolkarboksylsyrederivater.
NO138335C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive alkanolaminer
SE403774B (sv) Forfarande for framstellning av vissa terapeutiskt verksamma n-(merkaptoacyl)-aminosyror
NO138566C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,1,3-benzotiadiazol-derivater
NO145056C (no) (s)-1-aryloksy-2-propanolderivater for fremstilling av terapeutisk aktive (s)-1-aryloksy-3-amino-2-propanolderivater
NO137899C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n (1h-tetrazol-5-yl)-kinaldamider
NO142838C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater
IT8023445A0 (it) Capsula medicamentosa rigida enterosolubile.
BE827595A (fr) Medicament a administration par voie orale produisant un effet inhibiteur de l'antiplasmine
AR212858A1 (es) Procedimiento para la preparacion de derivados farmaceuticamente activos fenipolieno carboxilicos
IT8349395A0 (it) Prerarato farmaceutico a base di di gossina per ingestione orale
NO144928C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive zantinderivater.
NO145383C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte indoler.
NO145238C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive dihydrokarbostyril-derivater
NO144344C (no) Fremgangsmaate for fremstilling av terapeutisk aktive n-arylsulfonyl n`-(3-azabicykloalkyl)urinstoffer
NO146672C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cinnolinderivater
SE7513013L (sv) Sett att framstella 5,7-dihydroxi-tetrahydroisokinolinderivat och anvendning derav som lekemedel

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 7512740-7

Format of ref document f/p: F